Clinical breast cancer最新文献

{"title":"CBCT-Guided Online Adaptive Radiation Therapy for Accelerated Partial Breast Irradiation: A Single-Institution Experience.","authors":"Claudia Warden, Kayla Steed, Whitney Hotsinpiller, Joel Pogue, Joseph Harms, Michael Soike, Kimberly Keene, Michael Dobelbower, Markus Bredel, Dennis Stanley, D Hunter Boggs","doi":"10.1016/j.clbc.2025.08.018","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.018","url":null,"abstract":"<p><strong>Purpose/objectives: </strong>Accelerated partial breast irradiation (APBI) using stereotactic body radiation therapy (SBRT) offers shorter treatment, comparable local control, and improved cosmesis for early-stage breast cancer (ESBC). Cone beam CT (CBCT)-guided online adaptive radiation therapy (OART) enhances target coverage and minimizes normal tissue exposure. This retrospective study evaluates clinical characteristics and outcomes in patients treated with APBI using OART.</p><p><strong>Materials/methods: </strong>From January 2022 to May 2024, 40 patients (including 2 with bilateral disease) received SBRT with OART. Targets included the lumpectomy cavity (GTV), a 1 cm CTV margin, and a 3 mm PTV margin. Patients received 30 Gy in 5 fractions. Daily CBCT guided alignment and adaption of targets and organs-at-risk was performed. Either the scheduled or adapted plan was selected each day. Outcomes were assessed at 1 month and most recent follow-up using CTCAE criteria.</p><p><strong>Results: </strong>Patients (ages 50-83) had predominantly right-sided (59.5%) and upper outer quadrant tumors (61.9%), with a median size of 0.9 cm. The median interval from lumpectomy to radiation was 62 days; treatment lasted a median of 9 days. The adapted plan was used in 90% of fractions. At 1 month, 48% had no toxicity; all reported events were grade 1. At a median 14.3-month follow-up, most toxicities remained grade 1; 3 patients had grade 2 effects. No recurrences were observed.</p><p><strong>Conclusions: </strong>This study, the largest APBI with OART cohort to date, demonstrates excellent cosmesis, minimal toxicity, and promising early oncologic outcomes for ESBC patients.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiomics Analysis for Predicting Pathological Complete Response in Triple-Negative Breast Cancer and Reflecting Tumor Heterogeneity.","authors":"Yufei Wang, Lingfeng Ma, Shijin Yuan, Zhuo Wang, Xian Wang","doi":"10.1016/j.clbc.2025.08.014","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.014","url":null,"abstract":"<p><strong>Background: </strong>Heterogeneity in triple-negative breast cancer (TNBC) leads to different responses to neoadjuvant chemotherapy (NAC). NAC-resistant TNBC is often associated with higher risk of recurrence and poor prognosis. This study developed and validated a novel radiomics-based model to predict pathological complete response (pCR) to NAC and reflect tumor heterogeneity in TNBC.</p><p><strong>Methods: </strong>169 TNBC patients who underwent NAC between 2013 and 2023 were screened as a training cohort. A validation cohort and 2 cohorts containing RNA-seq data were also included. Radiomics features were extracted from dynamic contrast enhanced MRI (DCE-MRI) for model construction. Based on the model, we calculated the radiomics score (Rad-score) of each patient. The predictive capacity of the model was evaluated by area under receiver operating characteristic (ROC) curves. RNA-seq data was used to evaluate drug sensitivity, enriched pathways, and tumor microenvironment (TME) characteristics.</p><p><strong>Results: </strong>The radiomics model can predict pCR in both the training cohort (AUC = 0.902) and validation cohort (AUC = 0.775). The high Rad-score subgroup exhibited better response to chemotherapy and better prognosis. Immune activation-related pathways were also enriched in the high-score subgroup. The low-score subgroup showed enrichment of TGF-β-related pathways and was more sensitive to TGF-β inhibitor. The model can also identify immune phenotypes (AUC = 0.85). The high Rad-score subgroup had abundant immune cell infiltration, while the low Rad-score subgroup was lacking immune cells in TME.</p><p><strong>Conclusion: </strong>The model can effectively predict the pCR of TNBC and reflect tumor heterogeneity. Chemotherapy combined with targeting the TGF-β pathway is a potential strategy to overcome drug resistance in TNBC.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145102804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Topical Betamethasone Valerate and Olive Oil in Preventing Acute Radiation Dermatitis in Breast Cancer: A Randomized Double-Blind Placebo-Controlled Study.","authors":"Israa K Mohamed, Maggie M Abbassi, Mohamed R Kelany, Samar F Farid","doi":"10.1016/j.clbc.2025.08.008","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.008","url":null,"abstract":"<p><strong>Aim: </strong>The purpose of this study is to compare topical betamethasone-17-valerate and olive oil cream in preventing radiation-induced dermatitis (RID) in breast cancer patients and to provide prospective data evaluating the quality of life, subjective symptoms, and treatment satisfaction reported by the patients.</p><p><strong>Methods: </strong>This was a prospective, double-blind, randomized, parallel, placebo-controlled trial. A total of 132 patients were randomized into three groups to receive either olive oil cream (G1), betamethasone-17-valerate (Betnovate® cream, GlaxoSmithKline) (G2), or unmedicated cream base (G3) throughout radiotherapy (RT) and 2 weeks after. The study is registered on clinicaltrials.gov with ID: NCT05285943, Date: November 2021.</p><p><strong>Results: </strong>A total of 128 patients were included in the final analysis. Betamethasone and olive oil significantly differed from the unmedicated cream base at weeks 1 to 4 (P < 0.05). At week 5, only significance was observed between olive oil and unmedicated cream base (P = 0.013), and the mean RTOG (Radiation Therapy Oncology Group) score was significantly lower in olive oil and betamethasone groups than in the unmedicated cream base group (P < 0.05 at weeks 1-5) but, there was no significant difference between olive oil and betamethasone (P > 0.999). Furthermore, the percentage of patients who developed grade 3 at the end of the follow-up was significantly different between the olive oil group and the unmedicated cream base group (27.9% vs. 61%, P = 0.004). Additionally, olive oil and betamethasone had non-significant delayed grade 2 and grade 3 development (P > 0.999).</p><p><strong>Conclusion: </strong>Olive oil cream is as effective as betamethasone in alleviating RID in patients treated with adjuvant radiotherapy for breast cancer.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Performance of AI-Assisted Radiologists in Breast Cancer Detection Using Digital Mammography: A Systematic Review and Meta-Analysis.","authors":"Jiayin Lu, Xiaonan Xu, Yanyan Zhang, Kunyu Zhuang, Tali Fang, Chifa Zhang, Kairong Chen, Xiaomei Huang, Yingjia Li","doi":"10.1016/j.clbc.2025.08.013","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.013","url":null,"abstract":"<p><p>To evaluate the diagnostic performance of AI-assisted and standalone human radiologists in breast cancer detection using digital mammography (DM). A comprehensive search was conducted in PubMed, Web of Science, Embase, Cochrane Library, and Scopus databases for studies published from January 2019 to December 2024. Study quality was assessed using the quality assessment of diagnostic accuracy studies 2 (QUADAS-2) and quality assessment of diagnostic accuracy studies-comparative (QUADAS-C). Summary receiver operating characteristic (SROC) curves and prediction regions of pooled sensitivity, specificity, and estimated area under the curves (AUCs) were used to evaluate the diagnostic performance of AI-assisted radiologists versus standalone human radiologists. Sources of heterogeneity were explored using meta-regression analysis. Overall, 30 studies were included in the qualitative synthesis. Among them, data from 20 studies were separately utilized for quantitative synthesis, categorized into three scenario groups: concurrent assistant, AI reader-replacement, and additional reader scenarios. Pooled sensitivity was significantly higher for AI-assisted radiologists compared to standalone human radiologists in the concurrent scenario (0.84 vs. 0.78, P < .001), and pooled specificity was superior in the concurrent and replacement scenarios, respectively (0.84 vs. 0.80, P < .001; 0.96 vs. 0.95, P < .001). There were no significant differences in area under the curves (AUCs) among these three scenarios. In breast cancer diagnosis, AI-assisted radiologists demonstrated superior sensitivity compared to standalone human radiologists in the concurrent scenario, and superior specificity in both the concurrent and replacement scenarios. Further research is needed to confirm these findings and explore the optimal strategies for integrating AI into breast cancer diagnostic workflows.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of Compression Therapy at Different Pressure Levels on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Trial.","authors":"Hong Li, Yijing Fan, Huiqian Xu, Haihong Qu, Yang Wang, Dandan Yu, Lizhi Zhou","doi":"10.1016/j.clbc.2025.08.009","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.009","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to examine the effects of compression therapy at different pressure levels on chemotherapy-induced peripheral neuropathy (CIPN).</p><p><strong>Methods: </strong>A total of 108 breast cancer patients who developed CIPN after their first albumin-bound paclitaxel chemotherapy were randomly divided into 3 groups(1:1:1): control group, experimental group 1 (Grade II pressure: 23-32 mmHg), and experimental group 2 (Grade III pressure: 34-46 mmHg). The control group was given standard care, while the experimental groups underwent compression therapy in addition to standard care. CIPN incidence, symptom severity, and its impact on activities of daily living (ADL) were assessed at baseline, after the completion of the third and fifth chemotherapy cycles.</p><p><strong>Results: </strong>After completing 3 chemotherapy cycles, CIPN incidence did not differ significantly among the groups (P > .05). After 5 cycles, the incidence of CIPN (≥ Grade 1) was significantly lower in both experimental groups compared to the control group (P < .05), with Experimental Group 2 also showing lower CIPN incidence (≥ Grade 2) than the control and Experimental Group 1 (P < .05). Both Grade II and III compression therapies alleviated CIPN symptoms and improved ADL, but Experimental Group 2 demonstrated superior efficacy after 5 cycles (P < .05). Significant differences in symptom severity and ADL impact were observed across group, time, and interaction effects (P < .001).</p><p><strong>Conclusion: </strong>Compression therapy reduces CIPN incidence, alleviates symptoms, and improves ADL. Over longer intervention periods, Grade III pressure yields superior outcomes.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occupational Exposure to Ionizing Radiation in Female Physicians and Breast Cancer Risk: A Systematic Review and Meta-analysis.","authors":"Milena Martello Cristófalo, Yedda Nunes Reis, Jonathan Yugo Maesaka, Bruna Salani Mota, José Maria Soares Júnior, Edmund Chada Baracat, José Roberto Filassi","doi":"10.1016/j.clbc.2025.08.012","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.012","url":null,"abstract":"<p><strong>Introduction: </strong>Advancements in health technologies have enabled the performance of minimally invasive procedures using ionizing radiation for radioscopy and fluoroscopy by various physicians including orthopedic surgeons, radiologists, urologists, cardiologists, vascular surgeons, and plastic surgeons. Simultaneously, there appears to be an increasing frequency of breast cancer among these professionals. In addition to other risk factors to which they are exposed, ionizing radiation plays a role in carcinogenesis. This study is a systematic review and meta-analysis conducted to summarize the available literature on breast cancer risk among female physicians occupationally exposed to ionizing radiation.</p><p><strong>Methods: </strong>A systematic search was conducted in the PubMed, Embase, and LILACS databases, as well as reference lists based on PRISMA checklist (PROSPERO CRD42024553635). The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Statistical analyses were performed at Review Manager.</p><p><strong>Results: </strong>Six observational studies were included, evaluating 34,744 participants: 8103 exposed to ionizing radiation and 26,641 controls, with a minimum 10-year follow-up. According to the NOS, 5 studies were classified as high quality and one as moderate. The meta-analysis revealed an increased breast cancer risk among female physicians exposed to ionizing radiation, with an odds ratio (OR) 1.84 (95% CI 1.11-3.06). A sensitivity analysis excluding the study classified as moderate quality showed a breast cancer risk in the exposed group with an OR 1.42 (95% CI 1.06-1.89).</p><p><strong>Conclusions: </strong>Based on the results of this meta-analysis, female physicians occupationally exposed to ionizing radiation have an increased risk of breast cancer compared to those who are not exposed.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on Clinical Outcomes in Early-Stage Metaplastic Breast Cancer.","authors":"Kadri Altundag","doi":"10.1016/j.clbc.2025.08.010","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.010","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real World Safety of Adjuvant Ultra Hypofractionated Radiotherapy in Nonmetastatic Breast Cancer: Acute Cutaneous Toxicity and Aesthetic Outcomes.","authors":"Molka Mezghani, Mouna Ben Rejeb, Awatef Hamdoun, Rihab Haddad, Ghada Bouguerra, Lilia Ghorbal, Lotfi Kochbati","doi":"10.1016/j.clbc.2025.08.007","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.007","url":null,"abstract":"<p><strong>Background: </strong>Ultra-hypofractionated radiotherapy (U-HFRT) delivers a total dose in five fractions over one week and represents an emerging approach in the adjuvant treatment of breast cancer. However, concerns about toxicity continue to limit its widespread adoption in routine clinical practice. Skin toxicity, one of the most common side effects of breast RT, can significantly affect patients' quality of life and may lead to treatment interruptions.</p><p><strong>Objective: </strong>This prospective cohort study aimed to evaluate acute skin toxicity and aesthetic outcomes following U-HFRT and to identify predictive factors.</p><p><strong>Methods: </strong>A total of 102 patients who underwent breast-conserving surgery or mastectomy for localized breast cancer were included. Adjuvant RT was delivered at a dose of 26 Gy in 5 fractions over 1 week. A sequential boost of 10 Gy in 5 fractions was delivered to the tumor bed in selected patients who received whole-breast irradiation. Skin toxicity was assessed according to the CTCAE 4.03 scale, and aesthetic outcomes were evaluated using the Harvard classification.</p><p><strong>Results: </strong>The median age was 59.5 years. No radiodermatitis (RD) was observed in 42% of patients, while grade 1 and grade 2 RD occurred in 38.2% and 18.6% of cases, respectively. Only one patient experienced grade 3 RD. The peak of toxicity occurred on the tenth day after RT. Induration of the tumor bed was noted in 9.6% of patients receiving a boost versus 14.6% without a boost. A breast volume ≥ 714 cm3 was significantly associated with the occurence of RD. Clinical target volume receiving 105% of the prescribed dose ≥ 4.23% was associated with grade 2 RD. Aesthetic outcomes improved after a median follow-up of 8 months.</p><p><strong>Conclusion: </strong>U-HFRT appears to be a feasible and well-tolerated adjuvant treatment, with acceptable skin toxicity rates andfavorable aesthetic outcomes. However, a longer follow-up is necessary to assess long-term toxicities.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Incidence of Premature Bone Demineralization in Breast Cancer Patients Under 65.","authors":"Katherine Quesada Tibbetts, Kian Huang, Dayna Goltz, Millena Levin, Neelesh Prakash","doi":"10.1016/j.clbc.2025.08.006","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.006","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer patients face increased risks of low bone mineral density (BMD) and osteoporosis due to associated treatments and disease pathology. Current screening guidelines exclude patients under 65 years old, leaving younger patients vulnerable to premature bone loss and fractures.</p><p><strong>Methods: </strong>This study utilized PET-CT scans to predict BMD at the L1 vertebra. The use of Hounsfield Units (HU) from L1 CT scans has been shown to be a reliable predictor of T-scores from DEXA scans and can be used to predict osteoporosis risk in patients.</p><p><strong>Results: </strong>In this study, 385 patients under 65 years old with a diagnosis of breast cancer were analyzed. The median HU score of patients was 148.6 (Mean:155.9; Min: 35.19; Max: 539.05). Approximately 65% of patients had an HU score of less than 165, indicating a high likelihood of premature bone demineralization; 17% of low BMD patients were identified as within a range of osteoporosis.</p><p><strong>Significance: </strong>Our study reveals a high incidence of osteopenia and osteoporosis in breast cancer patients under 65, with 65% having HU scores indicative of early bone demineralization. This challenges existing osteoporosis screening guidelines, which do not include breast cancer as a risk factor for early screening. L1 vertebra PET-CT-derived HU measurements are effective for early low BMD detection and enable timely intervention. The study's significance lies in its potential to influence screening protocols, promote inclusive guidelines, and improve long-term bone health and outcomes in breast cancer patients through earlier detection and preventive care.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectory of Chemotherapy-Induced Peripheral Neuropathy and Its Predictive Factors in Breast Cancer Patients: A Prospective Longitudinal Study.","authors":"Huiqian Xu, Hong Li, Yijing Fan, Shufang Zhang, Yang Wang, Yiying Wang, Lizhi Zhou, Jinghua Zhang","doi":"10.1016/j.clbc.2025.08.002","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.08.002","url":null,"abstract":"<p><strong>Objective: </strong>To explore the trajectory patterns and influencing factors of chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients using latent class growth analysis (LCGA).</p><p><strong>Methods: </strong>This study was conducted from September 2022 to September 2023 at a tertiary hospital in Tangshan, China. A total of 350 hospitalized breast cancer patients undergoing chemotherapy were recruited. Data were collected through questionnaires, including general demographic information, disease-related characteristics, lifestyle factors, and psychological status. CIPN was assessed at 5 time points: baseline (T0) and the 21st day after the completion of the 1st (T1), 2nd (T2), 3rd (T3), and 4th (T4) chemotherapy cycles. Latent class growth models (LCGMs) were used to identify distinct trajectory patterns. Univariate analysis and multinomial logistic regression models were applied to examine the influencing factors.</p><p><strong>Results: </strong>Three distinct CIPN trajectory groups were identified: the low-risk stable group (42.3%, n = 148), the moderate-risk progressive group (41.4%, n = 145), and the high-risk rapidly progressing group (16.3%, n = 57). Compared with the low-risk stable group, the predictive factors for the moderate-risk progressive group included body mass index (BMI), hypertension, and depression. For the high-risk rapidly progressing group, predictive factors included BMI, physical activity, social support, hypertension, vitamin D levels, nutritional status, and depression.</p><p><strong>Conclusion: </strong>This study elucidates the heterogeneous trajectory patterns of chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients and identifies key influencing factors. Recognizing these characteristics in clinical practice may facilitate the early identification of high-risk patients and enable timely interventions to mitigate CIPN severity.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}